Pharmaceutics (Sep 2022)

Explaining the Release Mechanism of Ritonavir/PVPVA Amorphous Solid Dispersions

  • Adrian Krummnow,
  • Andreas Danzer,
  • Kristin Voges,
  • Stefanie Dohrn,
  • Samuel O. Kyeremateng,
  • Matthias Degenhardt,
  • Gabriele Sadowski

DOI
https://doi.org/10.3390/pharmaceutics14091904
Journal volume & issue
Vol. 14, no. 9
p. 1904

Abstract

Read online

In amorphous solid dispersions (ASDs), an active pharmaceutical ingredient (API) is dissolved on a molecular level in a polymeric matrix. The API is expected to be released from the ASD upon dissolution in aqueous media. However, a series of earlier works observed a drastic collapse of the API release for ASDs with high drug loads (DLs) compared to those with low DLs. This work provides a thermodynamic analysis of the release mechanism of ASDs composed of ritonavir (RIT) and poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA). The observed release behavior is, for the first time, explained based on the quantitative thermodynamic phase diagram predicted by PC-SAFT. Both liquid–liquid phase separation in the dissolution medium, as well as amorphous phase separation in the ASD, could be linked back to the same thermodynamic origin, whereas they had been understood as different phenomena so far in the literature. Furthermore, it is illustrated that upon release, independent of DL, both phenomena occur simultaneously for the investigated system. It could be shown that the non-congruent release of the drug and polymer is observed when amorphous phase separation within the ASD has taken place to some degree prior to dissolution. Nanodroplet formation in the dissolution medium could be explained as the liquid–liquid phase separation, as predicted by PC-SAFT.

Keywords